Systematic discovery

XAPIEN's chemosysteomics platform seeks to understand the medical implications of compound interactions with the entire Human system. Key to this approach is our aim to understand drugs, not from the perspective of their structural and physicochemical descriptors (i.e. chemotype), but according to the dictates of biology (i.e. biotype). A 'biotype' is considered to be the total complement of pharmacophoric and toxicophoric properties a compound possesses.

Once produced, our compound biotype information is assessed using a proprietary in silico analysis platform called PIPE-line (Pharmaceutical Intellectual Property Engine). By interfacing with our biomedical informatics infrastructure, PIPE-line will enable us to address issues such as combinatorial therapeutics, alternative medical uses (AMU), mode of actions (MOA), Adverse Drug Reactions (including drug:drug interactions), lead prioritisation/optimisation parameters, and patent space analysis.